Inspire ends denufosol retinal program
This article was originally published in Pharmaceutical Approvals Monthly
Inspire discontinues its Phase II pilot trials of the P2Y2 agonist denufosol (INS37217) for macular edema "and has no plans to conduct any further studies of denufosol for the treatment of retinal disease," the firm says Jan. 20. Data in two studies "did not demonstrate improvement in either reduction or retinal thickness or improvement in visual acuity." While the trials have been halted, Inspire will follow treated patients for one year. The company announced Jan. 30 that it is moving denufosol into Phase III for treatment of cystic fibrosis. Inspire has another P2Y2 agent, diquafosol, which is "approvable" for dry eye (1Pharmaceutical Approvals Monthly December 2005, p. 5)...
You may also be interested in...
Pfizer’s anidulafungin received a second “approvable” letter Nov. 25 for treatment of esophageal candidiasis, FDA said.
A patient recruiter got 10 years in prison for his role in a scheme to convince seniors to get unneeded and expensive genetic tests. Nicholas McQuaid, acting assistant attorney general of the Justice Department’s Criminal Division, discussed the case.
Wall Street is worried that a cluster of recent negative regulatory events means tougher reviews going forward. That concern is probably overdone, but a year into the COVID pandemic is a good time to take stock of how FDA is doing.